A Study YL201 in Patients With Selected Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and
Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will
include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with
expanded sample size (Part 2).
Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to
non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma
(NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate
cancer (mCRPC), etc..
Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to
further assess the efficacy and safety of YL201.